Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

Phase 1 Completed 18 enrolled Medical University of South Carolina

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as topotecan and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of topotecan when given together with vinorelbine in treating patients with recurrent lung cancer.

Timeline

Start: 2004-02
Primary completion: 2010-01
Completion: 2010-01

Publications

Results Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20;7:231. doi: 10.1186/1471-2407-7-231.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topotecan	Small molecule	2 mg/m2	Intravenous
Subject	Topotecan	Small molecule	2.5 mg/m2	Intravenous
Subject	Topotecan	Small molecule	3 mg/m2	Intravenous
Subject	Topotecan	Small molecule	3.5 mg/m2	Intravenous
Subject	Topotecan	Small molecule	4 mg/m2	Intravenous
Subject	Vinorelbine	Small molecule	20 mg/m2	Intravenous

Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

Summary

Timeline

Publications

Drugs

Indications